• Explore /
  • Poster
  • / Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.

Penpulimab plus chemotherapy with or without anlotinib as first-line treatment for patients with advanced esophageal squamous cell carcinoma (ANSWER): A randomized, two-arm, clinical trial in progress.

Abstract Poster

Authors

null

Wei Wang

Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China;

Wei Wang , Shuimiao Lin , Rong Wang , Dehua Wu

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT05214222

Citation

J Clin Oncol 41, 2023 (suppl 4; abstr TPS482)

DOI

10.1200/JCO.2023.41.4_suppl.TPS482

Abstract #

TPS482

Poster Bd #

N17

Abstract Disclosures

Similar Posters

First Author: Zhiwei Chang

First Author: Gong-Rang Chen

First Author: Xiuli Yang

First Author: Mingfang Xu